BSC
SMMT icon

BOLTON SECURITIES CORPORATION’s Summit Therapeutics SMMT Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-26,000
Closed -$379K – 2333
2026
Q2 		$379K Buy
26,000
+18,000
+225% +$319K 0.01% 681
2026
Q1 		$152K Buy
+8,000
New +$129K 0.01% 892
2025
Q3 		$165K Buy
+8,000
New +$194K 0.01% 796

Other funds holding SMMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Hohimer Wealth Management
Hohimer Wealth Management Seattle, Washington $1.03B AUM 25.45% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's SMMT Position: Q3 2026 in Review

BOLTON SECURITIES CORPORATION sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 26,000 shares — an estimated $379K sold.

BOLTON SECURITIES CORPORATION first reported a position in SMMT in Q3 2025 and held it in 3 quarters. The position peaked at $379K in Q2 2026. 163 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • BOLTON SECURITIES CORPORATION reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
  • BOLTON SECURITIES CORPORATION sold 26,000 Summit Therapeutics shares in Q3 2026, an estimated $379K.
  • BOLTON SECURITIES CORPORATION first reported a position in Summit Therapeutics in Q3 2025 and held it in 3 quarters.
  • BOLTON SECURITIES CORPORATION's Summit Therapeutics position peaked at $379K in Q2 2026.
  • 163 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q3 2026, filed 12 Nov 2026.